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ORIGINAL CONTRIBUTION JAMA-EXPRESS
Effects of Conjugated Equine Estrogen in
Postmenopausal Women With Hysterectomy
The Women’s Health Initiative Randomized Controlled Trial
The Women’s Health Initiative
Steering Committee*
ESTROGEN THERAPY HAS BEENavailable to postmenopausalwomen for more than 60 years.Proven benefits include relief of
vasomotor symptoms and vaginal at-
rophy and prevention and treatment of
osteoporosis. Observational studies pri-
marily examining unopposed estro-
gen preparations have suggested a 30%
to 50% reduction in coronary events,1-3
and an 8% to 30% increase in breast
cancer with extended use.4-6
The Women’s Health Initiative (WHI)
clinical trials of hormone therapy were
designed in 1991-1992 using the accu-
mulated evidence available at the time.7
Two parallel randomized, double-
blind, placebo-controlled clinical trials
of hormone therapy were undertaken to
determine whether conjugated equine
estrogen (CEE) alone (for women with
prior hysterectomy) or in combination
with progestin (medroxyprogesterone
acetate [MPA]) would reduce cardio-
vascular events in mostly healthy post-
menopausal women. The WHI estro-
gen plus progestin trial was halted in
July 2002 after a mean 5.2 years of fol-
low-up because health risks exceeded
benefits.8 Coronary heart disease (CHD),
stroke, and venous thromboembolic dis-
ease were all increased in women as-
signed to active treatment with estro-
gen plus progestin. Breast cancer was
also increased while colorectal cancer,
hip fracture, and other fractures were re-
duced. The lack of benefit for CHD was
*Author/Steering Committee Information, Finan-
cial Disclosures, and WHI Investigators appear at
the end of this article.
Context Despite decades of use and considerable research, the role of estrogen alone
in preventing chronic diseases in postmenopausal women remains uncertain.
Objective To assess the effects on major disease incidence rates of the most com-
monly used postmenopausal hormone therapy in the United States.
Design, Setting, and Participants A randomized, double-blind, placebo-
controlled disease prevention trial (the estrogen-alone component of the Women’s
Health Initiative [WHI]) conducted in 40 US clinical centers beginning in 1993. En-
rolled were 10739 postmenopausal women, aged 50-79 years, with prior hysterec-
tomy, including 23% of minority race/ethnicity.
Intervention Womenwere randomly assigned to receive either 0.625mg/d of con-
jugated equine estrogen (CEE) or placebo.
MainOutcomeMeasures The primary outcomewas coronary heart disease (CHD)
incidence (nonfatal myocardial infarction or CHD death). Invasive breast cancer inci-
dence was the primary safety outcome. A global index of risks and benefits, including
these primary outcomes plus stroke, pulmonary embolism (PE), colorectal cancer, hip
fracture, and deaths from other causes, was used for summarizing overall effects.
Results In February 2004, after reviewing data through November 30, 2003, the Na-
tional Institutes of Health (NIH) decided to end the intervention phase of the trial early.
Estimated hazard ratios (HRs) (95% confidence intervals [CIs]) for CEE vs placebo for the
major clinical outcomes available through February 29, 2004 (average follow-up6.8 years),
were: CHD, 0.91 (0.75-1.12) with 376 cases; breast cancer, 0.77 (0.59-1.01) with 218
cases; stroke, 1.39 (1.10-1.77) with 276 cases; PE, 1.34 (0.87-2.06) with 85 cases; co-
lorectal cancer, 1.08 (0.75-1.55) with 119 cases; and hip fracture, 0.61 (0.41-0.91) with
102 cases. Corresponding results for composite outcomes were: total cardiovascular dis-
ease, 1.12 (1.01-1.24); total cancer, 0.93 (0.81-1.07); total fractures, 0.70 (0.63-0.79);
total mortality, 1.04 (0.88-1.22), and the global index, 1.01 (0.91-1.12). For the out-
comes significantly affected by CEE, there was an absolute excess risk of 12 additional
strokes per 10000 person-years and an absolute risk reduction of 6 fewer hip fractures
per 10000 person-years. The estimated excess risk for all monitored events in the global
index was a nonsignificant 2 events per 10000 person-years.
Conclusions The use of CEE increases the risk of stroke, decreases the risk of hip
fracture, and does not affect CHD incidence in postmenopausal womenwith prior hys-
terectomy over an average of 6.8 years. A possible reduction in breast cancer risk re-
quires further investigation. The burden of incident disease events was equivalent in
the CEE and placebo groups, indicating no overall benefit. Thus, CEE should not be
recommended for chronic disease prevention in postmenopausal women.
JAMA. 2004;291:1701-1712 www.jama.com
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supported by the Heart and Estrogen/
progestin Replacement Study (HERS),
which also tested CEE plus MPA in
women with known coronary artery dis-
ease at baseline.9
Despite the early termination of the
WHI estrogen plus progestin trial, the
WHI estrogen-alone trial was contin-
ued with ongoing careful scrutiny by an
independent data and safety monitor-
ing board (DSMB) because the health
risks and benefits had not been ad-
equately determined. In February 2004,
the National Institutes of Health (NIH)
decided to terminate the intervention
phase of the estrogen-alone study, prior
to the scheduled close-out interval of Oc-
tober 2004 to March 2005. This report
presents the results of the estrogen-
alone trial using available data through
February 29, 2004, prior to notifying
participants of the decision on March 1,
2004. Subsequent detailed reports will
include additional outcomes occurring
between the participants’ last routine fol-
low-up and the date of trial termina-
tion. An ancillary study of dementia and
cognitive function will be reported sepa-
rately. Two remaining components of
the WHI clinical trial, testing the ef-
fects of a low-fat eating pattern and, in-
dependently, the effects of calcium plus
vitamin D supplementation, are con-
tinuing.
METHODS
Study Population and
Randomization
Detailed eligibility criteria and recruit-
ment methods have been published.7,10
Briefly, most participants were re-
cruited by population-based direct mail-
ing campaigns to age-eligible women, in
conjunction with local and national
media awareness programs. Women
were eligible if they were 50 to 79 years
old at initial screening, had undergone
hysterectomy (thereby considered post-
menopausal for enrollment purposes),
and were likely to reside in the area for
3 years. Major exclusions were related
to competing risks (any medical condi-
tion likely to be associated with a pre-
dicted survival of3 years), safety (eg,
prior breast cancer, other prior cancer
within the last 10 years except nonmela-
noma skin cancer), adherence and re-
tention concerns (eg, alcoholism, de-
mentia, and transportation problems),
or the clinical judgment of the partici-
pant’s health care practitioner to con-
tinue hormone therapy in symptom-
atic or osteoporotic women. A 3-month
washout period was required of women
using postmenopausal hormones at ini-
tial screening. Prior to the 1997 HERS
report,11 which led to a change in eligi-
bility criteria, 171 women with a his-
tory of venous thromboembolism (VTE)
were enrolled. The protocol and con-
sent forms were approved by the insti-
tutional review board for each partici-
pating institution (see the end of this
article), and all women provided writ-
ten informed consent.
Eligible women were randomly as-
signed to receive 0.625 mg/d of CEE
(Premarin; Wyeth, St Davids, Pa) or a
matching placebo, in equal propor-
tions. The computerized randomiza-
tion and blinding procedures have been
described.12 A small imbalance in the
number of women in each group was
a consequence of an early protocol
change eliminating a CEE-alone inter-
vention in women with a uterus.8
Follow-up and Data Collection
Study participants were contacted by
telephone 6 weeks after randomiza-
tion to assess symptoms and reinforce
adherence. Follow-up contacts by tele-
phone or clinic visit occurred every 6
months, with clinic visits required an-
nually. At each contact, adherence to
study medication was assessed, and in-
formation on symptoms, safety con-
cerns, and outcomes was collected.
Electrocardiograms were recorded at
baseline and at visit years 3, 6, and 9.
Annual mammograms and clinical
breast examinations were required;
study medication was withheld if these
safety procedures were not performed
or the results could not be verified. Par-
ticipants were followed up from the date
of entry until death, loss to follow-up,
or the time of a request for no further
contact, regardless of their adherence
to study medication. Baseline and year
1 lipid levels were measured in fasting
blood specimens from a random 8.6%
subsample of women. Methods for sub-
sampling, data collection and manage-
ment, and quality assurance have been
published.12
Maintenance/Discontinuation
of Study Medications
During the trial, women with intoler-
able symptoms such as breast tender-
ness were managed by reducing the
number of days per week that study
medication was taken. Participants and
study personnel remained blinded when
these adjustments were made. Study
medication was withheld in partici-
pants experiencing a myocardial infarc-
tion (MI), stroke, fracture or major in-
jury involving hospitalization, surgery
involving use of anesthesia, any illness
resulting in immobilization for longer
than 1 week, or any other severe illness
in which hormone use was considered
inappropriate. The decision to resume
study medication after MI or stroke was
left to the discretion of the clinical cen-
ter, individual participant, and her health
care clinician. Study medication was per-
manently discontinued in women who
developed breast cancer; deep vein
thrombosis (DVT) or pulmonary em-
bolism (PE); malignant melanoma; me-
ningioma; triglyceride level higher than
1000 mg/dL (11.3 mmol/L); or who
were treated by their personal health care
practitioners with prescription estro-
gen, testosterone, or selective estrogen
receptor modulators.
Outcome Ascertainment
Designated outcome events were evalu-
ated by review of medical records by
centrally trained physician adjudica-
tors at each clinical center who were
blinded to treatment assignment and
symptoms related to study medica-
tion. Final adjudication of key cardio-
vascular and cancer outcomes, as well
as hip fractures and deaths, was per-
formed centrally by comparably blinded
WHI physician adjudicators, neurolo-
gists, or cancer coders. Centrally adju-
dicated results are reported when avail-
able, with locally adjudicated events
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included when central adjudication has
not yet been completed. Centrally ad-
judicated results are available for 95.7%
of CHD events, 92.4% of strokes, 91.8%
of PE cases, 97.2% of breast cancers,
99.2% of colorectal cancers, 89.2% of
hip fractures, and 80.3% of deaths. De-
tailed outcome definitions and meth-
ods for ascertaining, documenting, and
classifying outcomes have been pub-
lished.13
Cardiovascular Disease. Coronary
heart disease was defined as acute MI
requiring overnight hospitalization, si-
lent MI determined from serial electro-
cardiograms obtained every 3 years, or
death due to CHD. Stroke was defined
as the rapid onset of a neurologic defi-
cit lasting more than 24 hours, sup-
ported by imaging studies in most cases
(89.8% had computed tomography/
magnetic resonance imaging [MRI]
studies available). Venous thrombo-
embolism was defined as PE or DVT
and required clinical symptoms sup-
ported by relevant diagnostic studies.
Total cardiovascular disease events in-
clude CHD, stroke, VTE, angina re-
quiring hospitalization, coronary re-
vascularization procedures, congestive
heart failure, carotid artery disease, and
peripheral vascular disease.
Cancer. All cancers other than non-
melanoma skin cancers were con-
firmed by pathology reports, available
for 98.2% of invasive breast, 95.0% of
colorectal, and 80.6% of other cancers.
Fractures. All reported clinical frac-
tures other than those of the ribs, chest/
sternum, skull/face, fingers, toes, and
cervical vertebrae were verified by re-
view of radiology, MRI, or operative re-
ports. WHI investigators did not ob-
tain spine radiographs to ascertain
subclinical vertebral fractures.
Global Index.A global index of risks
and benefits was defined for each
woman as the time to the first event
among the monitored outcomes (CHD,
stroke, PE, breast cancer, colorectal can-
cer, hip fractures, and death).14
Statistical Power and Analyses
The trial design assumed 12375 women
would need to be randomized to achieve
81% power to detect a 21% reduction
in CHD rates over the projected 9-year
average follow-up. This sample size
would provide 65% power to detect a
20% reduction in hip fracture rates. An
additional 5 years of follow-up with-
out intervention was planned to achieve
79% power to detect a 22% increase in
breast cancer risk.7 Calculations based
on the observed sample size and age dis-
tribution gave power estimates of 72%,
55%, and 71% for CHD, hip fracture,
and breast cancer, respectively.12
Lack of adherence to study medica-
tion was summarized at each fol-
low-up year as the cumulative propor-
tion of randomized participants who
had stopped taking study medications
(dropouts) and similarly the propor-
tion of women who began taking pre-
scription menopausal hormones
through their own health care practi-
tioner (drop-ins), after excluding pre-
ceding deaths. Participants were clas-
sified by their most recent status with
regard to study medications (stopped
or not). Thus, women who tempo-
rarily stopped taking study medica-
tion were considered adherent in this
analysis.
Event rate comparisons were based
on the intent-to-treat principle using
failure time methods. For a given out-
come, the time of event was defined to
be the number of days from random-
ization to the first postrandomization
diagnosis of the designated event. For
silent MIs, the date of the follow-up
electrocardiogram was used as the event
date. Follow-up time was censored at
the time of the last documented fol-
low-up contact or death. Compari-
sons of primary outcomes are pre-
sented as hazard ratios (HRs) and 95%
confidence intervals (CIs) from Cox
proportional hazard analyses,15 strati-
fied by age, prior disease, and random-
ization status in the low-fat diet trial.
Cumulative hazard rates were esti-
mated by the Kaplan-Meier method for
each designated outcome.
Two forms of CIs were calculated,
nominal and adjusted. This report pri-
marily presents the nominal 95% CIs
because they provide traditional esti-
mates of variability and, as such, are
comparable to most other reports of
hormone therapy studies. To acknowl-
edge multiple testing issues, adjusted
CIs were calculated using group se-
quential methods, and for secondary
outcomes a Bonferroni correction based
on the data and safety monitoring plan
(see below). Because the trial was near-
ing the planned termination, the im-
pact of the group sequential adjust-
ment on the width of the CIs is small.
The Bonferroni correction reflects the
study design and trial monitoring pri-
orities and hence may be somewhat less
relevant for interpreting the trial re-
sults. Unless otherwise indicated, all CIs
and P values are nominal. Statistical
analyses were performed using SAS ver-
sion 9.0 (SAS Institute, Cary, NC) and
significance was set at the .05 level.
The possibility of important sub-
group effects was explored by testing
for interactions in expanded Cox mod-
els. Because 23 interactions are re-
ported, chance alone could produce a
significant interaction at the .05 level
for approximately 1 factor in the se-
ries. Sensitivity analyses were con-
ducted to explore the possible impact
of lack of adherence to study medica-
tions. In these “complier” analyses, the
randomization assignment was pre-
served but follow-up for a woman was
censored 6 months after she first be-
came nonadherent (defined as taking
80% of study pills).
Data and Safety Monitoring
Statistical monitoring boundaries were
based on O’Brien-Fleming group
sequential procedures16 with asym-
metric boundaries for benefit (1-sided
.025-level upper boundary for CHD)
and adverse effects (1-sided .05-level
lower boundary). The adverse effect
boundary for the 6 monitored out-
comes of CHD, stroke, PE, hip frac-
tures, colorectal cancer, and death
from causes other than the monitored
disease outcomes incorporated a Bon-
ferroni correction. The Bonferroni cor-
rection was not applied to breast can-
cer because it was the primary safety
outcome. Early stopping was to be
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considered if a disease-specific bound-
ary was crossed and the global index
was supportive of the overall direction
of CEE effects. Formal monitoring of
disease rate comparisons began in the
fall of 1997 with trial termination
planned for March 2005. Additional
aspects of the monitoring plan have
been published.14
RESULTS
Trial Monitoring
and Early Stopping
In early 2000 and again in 2001, after
reviewing the data from the estrogen-
alone and the estrogen plus progestin
trials, the DSMB recommended that
participants in both trials be informed
of early increases in rates of heart dis-
ease, strokes, and blood clots in women
taking active hormone pills. In 2002,
with the early termination of the estro-
gen plus progestin trial, participants in
the estrogen-alone trial were in-
formed that no increase in breast can-
cer rates had been observed at that point
in women taking CEE. The DSMB con-
tinued to closely monitor the estrogen-
alone trial. The DSMB’s review of the
data for the 13th planned interim analy-
sis through August 31, 2003, plus an
unplanned analysis using data through
November 30, 2003, did not lead to a
consensus recommendation. None of
the predefined stopping boundaries had
been crossed, although the stroke com-
parison was approaching the adverse
effect boundary.
On February 2, 2004, following sub-
sequent reviews with additional advi-
sors, the NIH decided to stop the in-
tervention phase of the trial. The NIH
concluded that with an average of nearly
7 years of follow-up completed, CEE
does not appear to affect the risk of
heart disease, the primary outcome of
the study. Furthermore, the NIH found
an increased risk of stroke that was
similar to the risk reported from the es-
trogen plus progestin trial. Recogniz-
ing the risk of stroke, and the likeli-
hood that neither cardioprotection nor
breast cancer risk would be demon-
strated in the remaining intervention
period, the NIH deemed it unaccept-
able to subject healthy women in a pre-
vention trial to this risk.17 On March 1,
2004, participants were informed of the
trial termination and advised to stop
taking their study medication. Data
available through February 29, 2004,
by routine data collection are in-
cluded in this report.
Baseline Characteristics
Between 1993 and 1998, a total of
10739 women were randomized into
the estrogen-alone trial. Demographic
characteristics, medical history, and
health behaviors of these women have
been described in considerable de-
tail.18 In general, study participants were
healthy and at average risk of CHD and
breast cancer, although 441 (4.1%) with
Table 1. Baseline Demographic and Clinical Characteristics of the Women’s Health Initiative
Estrogen-Alone Trial Participants With Prior Hysterectomy (N = 10 739) by Randomization
Assignment*
Characteristics
CEE
(n = 5310)
Placebo
(n = 5429)
Age at screening, mean (SD), y 63.6 (7.3) 63.6 (7.3)
Age group at screening, y, No. (%)
50-59 1637 (30.8) 1673 (30.8)
60-69 2387 (45.0) 2465 (45.4)
70-79 1286 (24.2) 1291 (23.8)
Race/ethnicity, No. (%)
White 4007 (75.5) 4075 (75.1)
Black 782 (14.7) 835 (15.4)
Hispanic 322 (6.1) 333 (6.1)
American Indian 41 (0.8) 34 (0.6)
Asian/Pacific Islander 86 (1.6) 78 (1.4)
Unknown 72 (1.4) 74 (1.4)
Hormone use, No. (%)
Never 2769 (52.2) 2770 (51.1)
Past 1871 (35.2) 1948 (35.9)
Current† 669 (12.6) 708 (13.0)
Duration of prior hormone use, y, No. (%)‡
5 1352 (53.2) 1412 (53.1)
5-10 469 (18.5) 515 (19.4)
10 720 (28.3) 732 (27.5)
Body mass index, mean (SD)§ 30.1 (6.1) 30.1 (6.2)
Body mass index, No. (%)
25 1110 (21.0) 1096 (20.3)
25-29 1795 (34.0) 1912 (35.5)
30 2376 (45.0) 2383 (44.2)
Systolic BP, mean (SD), mm Hg 130.4 (17.5) 130.2 (17.6)
Diastolic BP, mean (SD), mm Hg 76.5 (9.2) 76.5 (9.4)
Smoking, No. (%)
Never 2723 (51.9) 2705 (50.4)
Past 1986 (37.8) 2089 (38.9)
Current 542 (10.3) 571 (10.6)
Parity, No. (%)
Never pregnant/no term pregnancy 489 (9.3) 461 (8.5)
1 Term pregnancy 4779 (90.7) 4932 (91.5)
Age at first birth, y, No. (%)
20 1193 (28.1) 1234 (28.0)
20-29 2846 (67.0) 2914 (66.1)
30 210 (4.9) 260 (5.9)
Abbreviation: CEE, conjugated equine estrogen.
*Subgroup totals may not sum to number randomized because of missing data.
†Required a 3-month washout prior to randomization.
‡Among women reporting hormone use.
§Measured as weight in kilograms divided by height in meters squared. Data available for 5281 CEE and 5391 placebo
participants.
Among women reporting 1 term pregnancy.
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prior MI or coronary revasculariza-
tion were enrolled. The intervention
groups were well balanced at baseline
on key demographic and disease risk
factor characteristics (TABLE 1 and
TABLE 2).
Follow-up, Adherence,
and Unblinding
Vital status is known for 10176 (94.8%)
of randomized participants, including
580 (5.4%) known to be deceased. Over
the average 6.8 years of follow-up
(range, 5.7-10.7 years), only 563
women (5.2%) withdrew, were consid-
ered lost to follow-up, or had stopped
providing outcomes information for
more than 18 months (FIGURE 1).
At the time of study termination,
53.8% of women had already stopped
taking study medication. Dropout rates
exceeded design projections, particu-
larly early on, but did not differ signifi-
cantly by randomization assignment
and were stable after year 1, even with
the termination of the estrogen plus
progestin trial (FIGURE2). Some women
initiated hormone use through their
own health care clinician: 5.7% of
women in the CEE group and 9.1% in
the placebo group by follow-up year 6.
These drop-in rates in the placebo
group were also somewhat greater than
expected. Reasons for initiating hor-
mone therapy outside of the study were
not captured. Unblinding of the study
gynecologist to randomization assign-
ment was infrequent, occurring for only
100 women in the CEE group and 83
in the placebo group. Per protocol, the
treatment assignment was not re-
vealed to other study staff members or
the study participants.
Intermediate Cardiovascular
Disease End Points
Fasting blood lipid levels, assessed in
an 8.6% subsample of women at base-
line and year 1, showed a greater re-
duction in low-density lipoprotein cho-
lesterol (−13.7% vs –1.0%,P.001) and
a larger increase in high-density lipo-
protein cholesterol (15.1% vs 1.1%,
P.001) in the CEE group compared
with the placebo group. Reductions in
total cholesterol from baseline to year
1 were comparable (−2.3% vs −1.4%,
P=.41). Larger increases in triglycer-
ide levels at year 1 were observed in the
CEE group than in the placebo group
(25.0% vs 3.0%, P.001). Systolic
blood pressure at 1 year was higher by
a mean (SE) of 1.1 (0.4) mm Hg in
women taking CEE than in women tak-
ing placebo (P = .003) and remained
similarly elevated throughout follow-
up. Diastolic blood pressures did not
differ significantly between the study
groups (data not shown).
Clinical Outcomes
Cardiovascular Disease. The primary
outcome for this trial was the rate of
CHD. The observed CHD incidence rate
of 51 per 10000 person-years was 15%
lower than projected in the design. No
significant effect of CEE was observed
on CHD rates compared with placebo
Figure 1. Participant Flow in the
Estrogen-Alone Component of the Women’s
Health Initiative
Status on
February 29, 2004
4757 Alive and Outcomes
Data Submitted in
Last 18 mo
136 Withdrew
126 Lost to Follow-up
291 Deceased
5310 Assigned to Receive
CEE
5429 Assigned to Receive
Placebo
11 941 Provided Consent and
Reported a Hysterectomy
373 092 Women Initiated Screening
10 739 Randomized
Status on
February 29, 2004
4839 Alive and Outcomes
Data Submitted in
Last 18 mo
185 Withdrew
116 Lost to Follow-up
289 Deceased
CEE indicates conjugated equine estrogen.
Table 2. Baseline Medical History Characteristics of the Women’s Health Initiative
Estrogen-Alone Trial Participants With Prior Hysterectomy (N = 10 739) by Randomization
Assignment*
Characteristics
CEE
(n = 5310)
Placebo
(n = 5429)
Age at hysterectomy, y, No. (%)
40 2100 (39.8) 2149 (39.8)
40-49 2281 (43.2) 2275 (42.2)
50-54 501 (9.5) 566 (10.5)
55 401 (7.6) 404 (7.5)
Bilateral oophorectomy, No. (%) 1938 (39.5) 2111 (42.0)
Medical treatment, No. (%)
Treated for diabetes 410 (7.7) 411 (7.6)
Treated for hypertension or BP 140/90 mm Hg 2386 (48.0) 2387 (47.4)
Elevated cholesterol levels requiring medication 694 (14.5) 766 (15.9)
Statin use at baseline 394 (7.4) 427 (7.9)
Aspirin use (80 mg/d) at baseline 1030 (19.4) 1069 (19.7)
Medical history, No. (%)
Myocardial infarction 165 (3.1) 172 (3.2)
Angina 308 (5.8) 306 (5.7)
CABG/PTCA 120 (2.3) 114 (2.1)
Stroke 76 (1.4) 92 (1.7)
DVT or PE 87 (1.6) 84 (1.5)
Female relative had breast cancer, No. (%) 893 (18.0) 870 (17.1)
Fracture at age 55 y, No. (%) 676 (14.0) 643 (13.2)
No. of falls in last 12 mo, No. (%)
0 3300 (67.0) 3230 (64.8)
1 975 (19.8) 1024 (20.5)
2 422 (8.6) 478 (9.6)
3 231 (4.7) 255 (5.1)
Abbreviations: BP, blood pressure; CABG/PTCA, coronary artery bypass graft/percutaneous transluminal coronary
angioplasty; CEE, conjugated equine estrogen; DVT, deep vein thrombosis; PE, pulmonary embolism.
*Subgroup totals may not sum to number randomized because of missing data.
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(49 vs 54 per 10000 person-years; 9%
reduction) (TABLE 3). These data rule
out a reduction in CHD rates with CEE
of more than 25% during the trial pe-
riod. The incidence of stroke was in-
creased by 39% in the CEE group (44
vs 32 per 10000 person-years, z=−2.72,
P=.007), which crossed the adverse
effect monitoring boundary for the 14th
planned interim analysis (defined as
z=−2.69). The risk of VTE, including
both DVT and PE, was increased for
women taking CEE (28 vs 21 per 10000
person-years; 33% increase), al-
though only the increased rate of DVT
reached statistical significance (P= .03).
Total cardiovascular disease event rates,
including stroke, were 12% higher in
women taking CEE (225 vs 201 per
10000 person-years, P=.02).
Cancer. Invasive breast cancer, the
primary safety outcome for this trial,
was diagnosed at a 23% lower rate in
the CEE group than in the placebo
group (26 vs 33 per 10000 person-
years) and this comparison narrowly
missed statistical significance (P=.06).
No significant differences were found
in rates of colorectal cancer for CEE vs
placebo (17 vs 16 per 10000 person-
years) or total cancer (103 vs 110 per
10000 person-years) (Table 3).
Fractures. Use of CEE reduced the
rates of fractures by 30% to 39%. Hip
fracture rates were 11 vs 17 per 10000
person-years (P=.01); clinical verte-
bral fractures, 11 vs 17 per 10000 per-
son-years (P=.02); and total osteopo-
rotic fractures, 139 vs 195 per 10000
person-years (P.001) (Table 3).
Summary Measures. The global in-
dex of health risks and benefits was bal-
anced overall (HR, 1.01; 95% CI, 0.91-
1.12). Of the 580 reported deaths,
94.8% have been adjudicated. Use of
Figure 2. Cumulative Drop-in and Dropout
Rates by Randomization Assignment and
Follow-up Duration
60
30
50
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Table 3. Clinical Outcomes by Randomization Assignment
Outcomes
No. of Patients
(Annualized %)
Hazard Ratio* Nominal 95% CI Adjusted 95% CI
CEE
(n = 5310)
Placebo
(n = 5429)
Follow-up time, mean (SD), mo 81.6 (19.3) 81.9 (19.7) NA NA NA
Cardiovascular disease†
CHD 177 (0.49) 199 (0.54) 0.91 0.75-1.12 0.72-1.15
CHD death 54 (0.15) 59 (0.16) 0.94 0.65-1.36 0.54-1.63
Nonfatal MI 132 (0.37) 153 (0.41) 0.89 0.70-1.12 0.63-1.26
Stroke 158 (0.44) 118 (0.32) 1.39 1.10-1.77 0.97-1.99
Fatal 15 (0.04) 14 (0.04) 1.13 0.54-2.34 0.38-3.36
Nonfatal 114 (0.32) 85 (0.23) 1.39 1.05-1.84 0.91-2.12
Venous thromboembolic disease 101 (0.28) 78 (0.21) 1.33 0.99-1.79 0.86-2.08
Deep vein thrombosis 77 (0.21) 54 (0.15) 1.47 1.04-2.08 0.87-2.47
Pulmonary embolism 48 (0.13) 37 (0.10) 1.34 0.87-2.06 0.70-2.55
Total cardiovascular disease 811 (2.25) 746 (2.01) 1.12 1.01-1.24 0.97-1.30
Cancer
Invasive breast 94 (0.26) 124 (0.33) 0.77 0.59-1.01 0.57-1.06
Colorectal 61 (0.17) 58 (0.16) 1.08 0.75-1.55 0.63-1.86
Total 372 (1.03) 408 (1.10) 0.93 0.81-1.07 0.75-1.15
Fractures
Hip 38 (0.11) 64 (0.17) 0.61 0.41-0.91 0.33-1.11
Vertebral 39 (0.11) 64 (0.17) 0.62 0.42-0.93 0.34-1.13
Total 503 (1.39) 724 (1.95) 0.70 0.63-0.79 0.59-0.83
Death
Due to other causes‡ 193 (0.53) 185 (0.50) 1.08 0.88-1.32 0.79-1.46
Total 291 (0.81) 289 (0.78) 1.04 0.88-1.22 0.81-1.32
Global index§ 692 (1.92) 705 (1.90) 1.01 0.91-1.12 0.89-1.14
Abbreviations: CEE, conjugated equine estrogen; CHD, coronary heart disease; CI, confidence interval; MI, myocardial infarction; NA, not applicable.
*From Cox proportional hazards model stratified by age, prior disease, and randomization status in the dietary modification trial.
†CHD includes acute MI requiring hospitalization, silent MI determined from serial electrocardiograms, and coronary death. There were 14 silent MIs. Total cardiovascular disease
is limited to events requiring or during hospitalization except venous thromboembolic disease reported after January 1, 2000.
‡All deaths except those from breast or colorectal cancer, definite/probable CHD, pulmonary embolism, or cerebrovascular disease.
§The global index represents the first event for each participant from among the following: CHD, stroke, pulmonary embolism, breast cancer, colorectal cancer, hip fracture, or
death due to other causes.
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CEE did not significantly affect total
mortality rates or cause-specific mor-
tality (TABLE 4).
Time Trends
Differences in cumulative hazards for
stroke and to a lesser extent for hip frac-
ture began to emerge early in the
intervention period and persisted
throughout follow-up (FIGURE 3). Cu-
mulative breast cancer hazard rates ap-
peared to separate beginning in year 2.
Similar displays for the global index and
death (FIGURE 4) reinforce the compa-
rability of these rates across treatment
groups. Tests for trends with time since
randomization were computed for all
of the monitored and composite out-
comes using a Cox proportional haz-
ards model with a time-dependent treat-
ment interaction term. Coronary heart
disease was the only outcome with a sta-
tistically significant trend (P=.02) of
slightly elevated HRs in the early fol-
low-up period that diminished over
time (year 1, 1.16; year 2, 1.20; year 3,
0.89; year 4, 0.79; year 5, 1.28; year 6,
1.24, and year 7, 0.42).
Further Analyses
Exploratory analyses were conducted
to determine whether selected partici-
pant characteristics modified CEE
effects on major clinical outcome
event rates. There were no significant
interactions between CEE and race/
Figure 3. Kaplan-Meier Estimates of Cumulative Hazards for Selected Clinical Outcomes
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Table 4. Causes of Death
No. (Annualized %)
CEE
(n = 5310)
Placebo
(n = 5429)
Total deaths 291 (0.81) 289 (0.78)
Adjudicated deaths 278 (0.77) 272 (0.73)
Cardiovascular 93 (0.26) 95 (0.26)
Breast cancer 4 (0.01) 8 (0.02)
Other cancer 110 (0.30) 118 (0.32)
Other known cause 51 (0.14) 38 (0.10)
Unknown cause 20 (0.06) 13 (0.04)
Abbreviation: CEE, conjugated equine estrogen.
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ethnicity or body mass index on risk of
CHD, stroke, VTE, breast cancer, co-
lorectal cancer, hip fracture, or total os-
teoporotic fracture (data not shown).
Of particular interest for all outcomes
was age at enrollment (FIGURE 5). The
only treatmentage interaction reach-
ing statistical significance was for
colorectal cancer (P=.048), for which
increasing age was associated with in-
creasing risk with CEE use.
The effect of prior disease on car-
diovascular event rates was also evalu-
ated. Among the 441 women enrolled
with prior MI or revascularization
procedures, the effect of CEE relative
to placebo (33 vs 31; HR, 1.04; 95%
CI, 0.63-1.71) did not differ signifi-
cantly from the CEE effect in women
without documented CHD (143 vs
162; HR, 0.91; 95% CI, 0.73-1.14)
(P= .55). Similarly, in 168 women
reporting prior stroke, the HR for sub-
sequent stroke (6 vs 6; HR, 1.67; 95%
CI, 0.52-5.36) did not differ from the
HR in women without a history of
stroke (152 vs 112; HR, 1.39; 95% CI,
1.09-1.78) (P=.77). Removing from
analysis the few participants with a
history of PE did not alter the hazard
ratio for PE substantially (47 vs 37;
HR, 1.31; 95% CI, 0.85-2.01).
Sensitivity analyses were conducted
to provide an indication of the poten-
tial impact of lack of adherence to as-
signed study medication. Compared
with the primary intent-to-treat analy-
ses (Table 3), the “complier” models es-
timated greater risks of stroke (HR,
1.74), pulmonary embolism (HR, 1.99),
and total mortality (HR, 1.26) but lower
risks of breast cancer (HR, 0.65), hip
fracture (HR, 0.48), and colorectal can-
cer (HR, 0.92). The HRs for CHD (HR,
0.89) and the global index (HR, 1.06)
were essentially unchanged.
COMMENT
The WHI estrogen-alone study was
a large-scale, randomized, double-
blind, placebo-controlled trial de-
signed to test the effects of the most
commonly used postmenopausal hor-
mone therapy preparation in the United
States19 on chronic disease incidence in
a diverse population of mostly healthy
postmenopausal women aged 50 to 79
years. As conceived, the study had ad-
equate power to detect moderate ef-
fects on CHD, hip fractures, and with
longer-term follow-up, breast cancer
among women across the broad age
range relevant for disease prevention
hypotheses. This trial demonstrated that
CEE increases the risk of stroke, re-
duces the risk of hip and other frac-
tures, but does not significantly affect
the incidence of CHD (the primary out-
come) or overall mortality. A nonsig-
nificant reduction in breast cancer
incidence requires additional investi-
gation. These observed risks and
benefits of CEE for chronic disease rates
appear to be balanced over an average
6.8-year follow-up period.
The lack of effect of CEE on CHD
risk is substantially different from the
favorable reports from observational
studies that motivated this trial, and was
observed despite an improvement in
cholesterol levels. However, these re-
sults are consistent with several re-
cent secondary prevention trials that
showed no benefit of hormone therapy
on atherosclerosis or clinical events.20-24
The current study suggests that younger
women who use CEE may be at re-
duced risk of CHD but this possible as-
sociation may be due to chance.
These CHD results for CEE also
differ importantly from 2 previous
trials of estrogen plus progestin. In
both the WHI estrogen plus progestin
trial25 and HERS,26 the risk of CHD
was significantly elevated in the first
year of treatment and the cumulative
effects of estrogen plus progestin
never appeared beneficial. In the cur-
rent study, a smaller, nonsignificant
increase was observed in the first year
of CEE exposure but the cumulative
effect suggests a possible modest ben-
efit with longer-term use. Potential
explanations for this discrepancy
include the role of progestin, differ-
ences in the study populations in
baseline risk factors,18 duration of
intervention and follow-up time, and
the role of chance.
The observed adverse effect of CEE
on the risk of stroke is consistent with
the risks reported by the WHI and HERS
estrogen plus progestin trials.27,28 In ad-
dition, the use of estradiol in women af-
ter ischemic stroke resulted in no change
in mortality but a higher rate of recur-
rent nonfatal stroke and a suggestion of
more severe functional deficits.29 The
small but persistent increase in systolic
Figure 4. Kaplan-Meier Estimates of Cumulative Hazards for Global Index and Death
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blood pressure in women taking CEE is
one possible contributor to this effect be-
cause relatively small differences in sys-
tolic blood pressure have been posi-
tively associated with differences in
stroke and cardiovascular disease
rates.30,31
The WHI estrogen-alone trial pro-
vides strong evidence that CEE reduces
the risk of hip, clinical vertebral, and
other fractures. These reductions were
of similar magnitude to those observed
in the WHI estrogen plus progestin trial32
and are consistent with findings from
prior observational studies33,34 and re-
cent meta-analyses.35-37
The trend toward a reduction in
breast cancer incidence was unantici-
pated and is opposite of that observed
in the WHI estrogen plus progestin trial,
which reported a 24% increased risk.38
These results also appear contrary to the
preponderance of observational study
results,4,39 including those from the re-
cent Million Women Study.40 When ex-
amining breast cancer risk by type of
hormone therapy, most of these stud-
ies have reported a modest increase in
breast cancer risk with estrogen alone
but a greater risk for estrogen plus pro-
gestin. Still others have recently found
little or no effect of estrogen alone on
breast cancer risk.41 Differences in
breast cancer screening between the
CEE and placebo groups do not ex-
plain the observed breast cancer ef-
fects because the WHI protocol man-
dated annual mammography and
clinical breast examinations. The pos-
sibility that diagnostic delay could ac-
count for this reduction seems remote
because the effect of CEE alone on
breast density is minimal.42 Longer-
term effects of CEE on breast cancer risk
remain uncertain. Extended follow-
up, as is currently planned, and analy-
ses of breast cancer characteristics simi-
lar to those reported for the estrogen
Figure 5. Selected Clinical Outcomes by Participant Age and Randomization Assignment
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plus progestin study38 may provide ad-
ditional insight.
In preliminary subgroup analyses, the
estimated HRs for CEE for several moni-
tored outcomes, including the global in-
dex, were lower for women aged 50 to
59 years, although differences in HRs
across age groups were not statistically
significant. While these results suggest
that CEE may be somewhat more favor-
able in younger than in older women,
these subgroup analyses must be inter-
preted with caution; we cannot exclude
the role of chance or limited power.
Limitations
This trial was designed to test only one
unopposed estrogen preparation at a
single dose, administered orally. We
cannot determine whether these re-
sults would apply to other formula-
tions, doses, or routes of administra-
tion. Care is needed in making
comparisons of these estrogen-alone
trial results to those of the estrogen plus
progestin trial, even though this is of
considerable interest. The differences
between these 2 study populations in
their baseline characteristics,18,43 their
event rates, the length of intervention
and follow-up time, and the complete-
ness of data at this initial report are suf-
ficient to make simple contrasts poten-
tially misleading. More detailed analyses
of these parallel trials are planned.
The high rates of discontinuation of
study medications and higher than ex-
pected crossover from placebo to ac-
tive hormone use are further limita-
tions. The rate of discontinuation is less
than what is usually observed in clini-
cal practice44 and was similar in the 2
groups. The somewhat higher drop-in
rate in the placebo group is not ex-
plained by unblinding, which was in-
frequent (1.5%) and similar in the 2
groups. Sensitivity analyses suggest that
the lack of adherence to assigned study
medication may have diluted the CEE
effects, both positive and negative, rela-
tive to what might be observed with full
adherence, but it did not distort the
overall balance of effects.
Lower than anticipated event rates for
some outcomes, particularly CHD and
hip fractures, reduce the power rela-
tive to what was originally projected but
reinforce the generally healthy status of
these participants. The fact that the trial
was stopped early further decreases the
precision of the estimated effects. A
longer intervention period may have
provided stronger statistical evidence of
CEE effects, particularly for CHD, for
which some evidence of a trend with
time was observed, and for breast can-
cer, for which the cumulative effect of
long-term exposure remains uncer-
tain. Additional data could have al-
lowed for more informative subgroup
analyses. Extended follow-up of these
women without further intervention is
planned.
Clinical Implications
In women aged 50 to 79 years reporting
a prior hysterectomy, CEE did not affect
CHD rates but did increase the risk of
stroke, accounting for an excess risk of
12 cases per 10000 person-years, and re-
duced the risk of hip fractures, result-
ing in 6 fewer cases per 10000 person-
years. Unexpectedly, women taking CEE
also appeared to be diagnosed as hav-
ing breast cancer at a lower rate than
women taking placebo, but the esti-
mated 7 fewer cases per 10000 person-
years did not reach statistical signifi-
cance. The totality of monitored effects,
as summarized in the prespecified global
index, suggests an overall balance of risks
and benefits and importantly no effect on
total mortality.
Based on these findings, women and
their health care professionals now have
usable risk estimates for the benefits and
harms of CEE alone. Women consid-
ering taking CEE should be counseled
about an increased risk of stroke but can
be reassured about no excess risk of
heart disease or breast cancer for at least
6.8 years of use. At present, these data
demonstrate no overall benefit of CEE
for chronic disease prevention in post-
menopausal women and thus argue
against its use in this setting. Overall,
these data support the current US Food
and Drug Administration recommen-
dations for postmenopausal women to
use CEE only for menopausal symp-
toms at the smallest effective dose for
the shortest possible time.45
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